Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cimetidine as an immune response modifier.

R Hast1, P Bernell, M Hansson

  • 1Department of Medicine, Danderyd Hospital, Stockholm, Sweden.

Medical Oncology and Tumor Pharmacotherapy
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring research participants' perceptions of cardiovascular risk information-Room for improvement and empowerment.

Patient education and counseling·2019
Same author

Optimization of soft X-ray phase-contrast tomography using a laser wakefield accelerator.

Optics express·2019
Same author

A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia.

NPJ precision oncology·2018
Same author

Greenland records of aerosol source and atmospheric lifetime changes from the Eemian to the Holocene.

Nature communications·2018
Same author

Unique case of cerebrotendinous xanthomatosis revisited: All the mutations responsible for this disease are present in the CYP27A1 gene.

Journal of internal medicine·2017
Same author

Highly efficient angularly resolving x-ray spectrometer optimized for absorption measurements with collimated sources.

The Review of scientific instruments·2017
Same journal

Treatment of ovarian cancer: the state of the art.

Medical oncology and tumor pharmacotherapy·1993
Same journal

Clinical evaluation of the CORDIS vascular access port systems: a multicenter study.

Medical oncology and tumor pharmacotherapy·1993
Same journal

Expression of an adhesion molecule and homing in B-cell chronic lymphocytic leukaemia: I. Application of the HEV-binding assay to a clinical series.

Medical oncology and tumor pharmacotherapy·1993
Same journal

Ultrastructural investigation of DNA in megakaryoblastic leukemia by using osmium-ammine-B: comparison with several types of leukemia.

Medical oncology and tumor pharmacotherapy·1993
Same journal

T-lymphocyte sub-populations in orbito-ocular granulocytic sarcoma (OOGS) and acute myelocytic leukemia (AML): a preliminary study.

Medical oncology and tumor pharmacotherapy·1993
Same journal

Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma.

Medical oncology and tumor pharmacotherapy·1993
See all related articles

Cimetidine, a histamine-2 receptor antagonist, may boost immune function by influencing T-lymphocytes and enhancing natural killer cell activity. It shows promise in restoring immunity for various immune disorders.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Cimetidine is a histamine-2 receptor antagonist.
  • It is being investigated for its immune-modifying potential.

Purpose of the Study:

  • To explore cimetidine's role in modulating immune responses.
  • To understand the mechanisms behind cimetidine's immune effects.

Main Methods:

  • Review of existing studies on cimetidine and immune function.
  • Analysis of cimetidine's impact on T-lymphocytes, NK cell activity, and cytotoxicity.

Main Results:

  • Cimetidine appears to stimulate the immune system.
  • It may block histamine receptors on T-lymphocytes, reducing immune suppression.
  • Studies indicate increased natural killer cell activity and antibody-dependent cellular cytotoxicity.

Related Experiment Videos

Conclusions:

  • Cimetidine demonstrates immune-stimulatory properties.
  • It has shown success in improving immune function in patients with malignant disorders, hypogammaglobulinemia, and AIDS-related complexes.